For the year ending 2025-12-31, AQST made $44,545K in revenue. -$83,784K in net income. Net profit margin of -188.09%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenues | 44,545 | |||
| Manufacture and supply | 18,555 | |||
| Research and development | 17,192 | |||
| Selling, general and administrative | 79,849 | |||
| Total costs and expenses | 115,596 | |||
| Loss from operations | -71,051 | |||
| Interest expense | 11,120 | |||
| Interest expense related to royalty obligations | 5,737 | |||
| Interest expense related to the sale of future revenue | 243 | |||
| Interest income and other income, net | 4,367 | |||
| Net loss before income taxes | -83,784 | |||
| Income taxes benefit | 0 | |||
| Net loss | -83,784 | |||
| Comprehensive loss | -83,784 | |||
| Basic EPS | -0.78 | |||
| Diluted EPS | -0.78 | |||
| Basic Average Shares | 106,926,528 | |||
| Diluted Average Shares | 106,926,528 | |||
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)